Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CGTX | US
0.00
0.20%
Healthcare
Biotechnology
30/06/2024
30/08/2024
0.71
0.69
0.72
0.68
Cognition Therapeutics Inc. a clinical-stage biopharmaceutical company engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812 an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease. The company is also developing COG0201 SHINE a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial. Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration. The company was incorporated in 2007 and is headquartered in Purchase New York.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
71.0%1 month
107.0%3 months
136.1%6 months
109.2%-
-
1.24
0.03
0.02
-0.44
-
-
-58.61M
28.55M
28.55M
-
-
-
-
-108.31
0.30
2.33
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.17
Range1M
0.50
Range3M
1.99
Rel. volume
0.24
Price X volume
136.73K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Common Stock | NRBO | Biotechnology | 3.69 | 31.32M | 5.13% | n/a | 0.00% |
Achilles Therapeutics plc American Depositary Shares | ACHL | Biotechnology | 0.72 | 30.75M | -2.23% | n/a | 3.86% |
PLUR | PLUR | Biotechnology | 5.7 | 30.72M | -2.40% | n/a | -8450.28% |
DarT Bioscience Inc | DARE | Biotechnology | 3.58 | 30.60M | 0.85% | 0.11 | 218.34% |
QNCX | QNCX | Biotechnology | 0.691 | 29.90M | -0.33% | n/a | 0.00% |
ImmuCell Corporation | ICCC | Biotechnology | 3.74 | 29.30M | -1.84% | n/a | 67.52% |
Longeveron Inc. Class A Common Stock | LGVN | Biotechnology | 2.04 | 29.29M | -2.39% | n/a | 11.72% |
Gain Therapeutics Inc. Common Stock | GANX | Biotechnology | 1.09 | 27.83M | 1.87% | n/a | 6.85% |
Unity Biotechnology Inc | UBX | Biotechnology | 1.63 | 27.46M | -1.81% | n/a | 0.00% |
SABS | SABS | Biotechnology | 2.94 | 27.13M | 1.38% | n/a | 11.58% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 2.34 | 28.51M | 13.04% | n/a | 16.03% |
ILAG | ILAG | Building Products & Equipment | 1.25 | 22.57M | 6.84% | n/a | 5.48% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 0.6131 | 18.67M | -4.20% | n/a | 204.46% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2495 | 3.93M | 5.94% | n/a | 0.00% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.391 | 3.72M | -6.28% | n/a | 19.98% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.45 | 3.70M | 13.28% | n/a | 9.62% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.47 | 2.11M | -7.84% | n/a | 0.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.44 | 0.97 | Cheaper |
Ent. to Revenue | - | 3,681.29 | - |
PE Ratio | - | 39.83 | - |
Price to Book | 1.24 | 14.54 | Cheaper |
Dividend Yield | - | 2.19 | - |
Std. Deviation (3M) | 136.11 | 76.13 | Riskier |
Debt to Equity | 0.03 | -2.05 | Expensive |
Debt to Assets | 0.02 | 0.25 | Cheaper |
Market Cap | 28.55M | 4.04B | Emerging |